Pharming Group N.V. PHAR
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -30.79%
- 1 year
- -6.93%
- Open
- 12.18
- Prev close
- 12.24
- Mkt cap
- 865.62M
- Vol
- 14.05K
- Avg vol
- 24.59K
- EPS
- 0.32
- P/E
- 38.22
- Div yield
- 0.00%
More statistics
- Low
- 12.09
- High
- 12.31
- Forward P/E
- 216.49
- Beta
- 0.09
- Short ratio
- 0.38
- Inst. own
- 0.14%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.57
- 200-d avg
- 15.63
- 1y target
- 34.35
News
-
2 days ago benzinga.com
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41
Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $38 to $41.
4 days ago seekingalpha.com
Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript
Pharming Group N.V. ( PHAR ) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDT Company Participants Kenneth Lynard - CFO & Co-Chief Executive Officer Leverne Marsh - Co-CEO & Chief Commercial…
4 days ago marketbeat.com
Pharming Group Q3 Earnings Call Highlights
Pharming Group NASDAQ: PHAR reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated…
4 days ago benzinga.com
Pharming Q3 2026 Earnings Call Transcript
Pharming (NASDAQ:PHAR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
5 days ago benzinga.com
Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
-
5 days ago benzinga.com
Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 200 percent increase over earnings of $0.10 per…
5 days ago globenewswire.com
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared…
1 week ago benzinga.com
Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday
U.S. stocks fell Friday, but Selective Insurance surged after beating EPS estimates, approving a $200M buyback and raising its dividend.
1 week ago benzinga.com
Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings
U.S. stocks fell, led by a 2% Nasdaq drop; Lockheed Martin beat estimates and raised guidance. Oil rose, while global markets and metals declined.
1 week ago benzinga.com
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, but Healthcare Services Group jumped 8.2% on an earnings beat. Biohaven led gainers, surging 30.5% after FDA news.
-
1 week ago benzinga.com
Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est
Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
-
1 week ago benzinga.com
Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in…
-
2 weeks ago benzinga.com
Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was…
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding…
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
5 months ago benzinga.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
5 months ago benzinga.com
Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.
7 months ago benzinga.com
Earnings Scheduled For March 12, 2026
Earnings Scheduled For March 12, 2026
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
11 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
3 years ago benzinga.com
Earnings Scheduled For October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.